Literature DB >> 2005454

Comparison of myocardial imaging with iodine-123-iodophenyl-9-methyl pentadecanoic acid and thallium-201-chloride for assessment of patients with exercise-induced myocardial ischemia.

P Chouraqui1, J Maddahi, R Henkin, S M Karesh, E Galie, D S Berman.   

Abstract

Iodine-123-iodophenyl-9-methyl-pentadecanoic acid [( 123I]MPDA) and thallium-201 (201Tl) were sequentially injected in 11 patients during exercise-induced myocardial ischemia. Simultaneous dual-energy planar images were obtained at 5 min, 3 and 5 hr. All studies were concordantly either positive (8/11) or negative (3/11) by both radionuclides. Exact agreement for segmental uptake was 93%, 94% and 94% for 5-min, 3- and 5-hr images, respectively. Exact agreement for defect reversibility by 3 and 5 hr were 95% and 92%. The initial defect contrasts and myocardial-to-lung ratios were similar by both agents but myocardial-to-liver ratio was lower by [123I]MPDA at 5 min, which became similar to 201Tl at 5 hr. Normal percent myocardial clearances of both agents were comparable and significantly higher than those in defect zones. Thus [123I]MPDA is suitable for myocardial imaging and correlates closely with 201Tl for initial postexercise myocardial uptake and defect reversibility. Defect reversibility appears to result from differential myocardial clearance from normal and ischemic regions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2005454

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  10 in total

Review 1.  Complementarity of magnetic resonance spectroscopy, positron emission tomography and single photon emission tomography for the in vivo investigation of human cardiac metabolism and neurotransmission.

Authors:  A Syrota; P Jehenson
Journal:  Eur J Nucl Med       Date:  1991

Review 2.  Iodine-123-labelled fatty acids for myocardial single-photon emission tomography: current status and future perspectives.

Authors:  F F Knapp; J Kropp
Journal:  Eur J Nucl Med       Date:  1995-04

Review 3.  Radionuclide assessment of myocardial fatty acid metabolism by PET and SPECT.

Authors:  N Tamaki; Y Fujibayashi; Y Magata; Y Yonekura; J Konishi
Journal:  J Nucl Cardiol       Date:  1995 May-Jun       Impact factor: 5.952

Review 4.  Rationale for the rational development of new cardiac imaging agents.

Authors:  D D Miller
Journal:  Ann Nucl Med       Date:  1993-11       Impact factor: 2.668

Review 5.  Metabolic imaging using SPECT.

Authors:  Junichi Taki; Ichiro Matsunari
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06       Impact factor: 9.236

6.  Both total chain length and position of dimethyl-branching effect the myocardial uptake and retention of radioiodinated analogues of 15-(p-iodophenyl)-3,3-dimethylpentadecanoic acid (DMIPP).

Authors:  F F Knapp; M M Goodman; G Kirsch; S N Reske; J Kropp; H J Biersack; K R Ambrose; C R Lambert; A Goudonnet
Journal:  Ann Nucl Med       Date:  1996-02       Impact factor: 2.668

7.  Impaired myocardial fatty acid metabolism detected by 123I-BMIPP in patients with unstable angina pectoris: comparison with perfusion imaging by 99mTc-sestamibi.

Authors:  Y Takeishi; H Sukekawa; H Saito; S Nishimura; T Shibu; Y Sasaki; H Tomoike
Journal:  Ann Nucl Med       Date:  1995-08       Impact factor: 2.668

8.  Detection of viable myocardium with p-iodophenyl-9-(R,S)-methylpentadecanoic acid in ischemic rat myocardium.

Authors:  Shinji Hasegawa; Hideo Kusuoka; Kaoru Maruyama; Hiroyuki Kurosawa; Syusaku Tazawa; Satoshi Ishida; Minoru Inoue; Masatsugu Hori; Tsunehiko Nishimura
Journal:  J Nucl Cardiol       Date:  2002 Sep-Oct       Impact factor: 5.952

9.  Uridine: a marker of myocardial viability after coronary occlusion and reperfusion.

Authors:  H Yaoita; A J Fischman; H W Strauss; T Saito; E Sato; Y Maruyama
Journal:  Int J Card Imaging       Date:  1993-12

10.  A data sheet for the simultaneous assessment of dual radioactive tracer uptake in the heart.

Authors:  Takao Kato
Journal:  MethodsX       Date:  2016-04-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.